Bayer confirms group guidance for 2025

Based on the company’s business performance overall in the first nine months of the year, CEO Bill Anderson confirmed the upgraded full-year Group guidance that was published in the 2025 Half-Year Financial Report. For Consumer Health, Bayer (BAYRY) now projects currency- and portfolio-adjusted sales growth of minus 1 to plus 1 percent as the division navigates an increasingly challenging market environment. The company had previously expected currency- and portfolio-adjusted sales growth at the division to come in at the lower end of the projected range of 2 to 5 percent. However, it does not anticipate any impact with respect to its guidance for the division’s EBITDA margin before special items. In view of the additional allocations to provisions for litigations in the third quarter, Bayer now expects special items in full-year Group EBITDA to come in at minus 4.0 to minus 3.5 billion euros, previous forecast: minus 3.5 to minus 2.5 billion euros, and special items in full-year Group EBIT to come in at minus 3.0 to minus 2.5 billion euros, previous forecast: minus 2.5 to minus 1.5 billion euros/